Novem Group Invests $831,000 in Agilent Technologies, Inc. (NYSE:A)

Novem Group acquired a new position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,187 shares of the medical research company's stock, valued at approximately $831,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in A. Norges Bank bought a new position in Agilent Technologies during the fourth quarter valued at approximately $456,963,000. Madison Investment Advisors LLC purchased a new stake in shares of Agilent Technologies in the 4th quarter valued at $94,051,000. Two Sigma Investments LP grew its holdings in shares of Agilent Technologies by 345.9% during the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock valued at $103,428,000 after purchasing an additional 597,249 shares during the last quarter. Iron Triangle Partners LP bought a new position in shares of Agilent Technologies during the 4th quarter valued at $80,110,000. Finally, Marshall Wace LLP raised its position in Agilent Technologies by 280.3% in the 4th quarter. Marshall Wace LLP now owns 806,895 shares of the medical research company's stock worth $108,398,000 after purchasing an additional 594,744 shares during the period.

Insider Transactions at Agilent Technologies

In related news, VP Rodney Gonsalves sold 1,908 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the sale, the vice president now owns 21,786 shares of the company's stock, valued at $2,657,456.28. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the company's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the sale, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. This trade represents a 4.84% decrease in their position. The disclosure for this sale can be found here.

Analysts Set New Price Targets

A has been the subject of several analyst reports. Jefferies Financial Group cut their price target on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Barclays dropped their target price on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Wells Fargo & Company decreased their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. TD Cowen boosted their price objective on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Finally, Robert W. Baird cut their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Agilent Technologies has a consensus rating of "Moderate Buy" and an average price target of $143.00.

Agilent Technologies Stock Down 4.1%

Shares of Agilent Technologies stock opened at $108.83 on Thursday. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $154.49. The company has a market cap of $31.03 billion, a P/E ratio of 25.02, a PEG ratio of 3.20 and a beta of 1.27. The company's fifty day simple moving average is $109.98 and its two-hundred day simple moving average is $127.76.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Research analysts anticipate that Agilent Technologies, Inc. will post 5.54 EPS for the current year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.